Acorda Shares Fall as Court Denies Injunction Request in Patent Case -- Market Mover
2018年7月26日 - 3:36AM
Dow Jones News
Acorda Therapeutics Inc. (ACOR) were down 14.8%, to $24.45,
Wednesday afternoon as a federal appeals court denied the company's
motion for an injunction in its patent litigation with generic drug
companies. In 2017, after a district court upheld one patent for
multiple sclerosis treatment Ampyra, but invalidated four others,
Acorda said it would cut about 20% of its workforce. If the appeals
court doesn't overturn the district court's decision by July 30,
"multiple generic drug manufacturers may decide to launch at-risk
generic versions of Ampyra," the company said in a filing.
(josh.beckerman@wsj.com)
(END) Dow Jones Newswires
July 25, 2018 14:21 ET (18:21 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024